RODRIGO RAMELLA MUNHOZ
Projetos de Pesquisa
Unidades Organizacionais
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
31 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 31
- PET/CT in soft tissue sarcomas(2022) ETCHEBEHERE, E.; MUNHOZ, R. R.; CASALI, A.; ETCHEBEHERE, M.Soft tissue sarcomas are a diverse group of rare malignant tumors of mesenchymal origin. Clinical diagnosis of soft tissue sarcoma poses a dilemma since the differentiation of a benign from a malignant lesion might be challenging. In addition to the risk of local relapse, these tumors may metastasize, mainly to the lungs, but also to other tissues, and evaluation of the extent of disease and subsequent response to therapy may be difficult. Following local or systemic therapies, tumor fibrosis might occur and can be confounded with viable tumor tissue. FDG PET/CT is a molecular imaging modality that uses the tumor metabolism to evaluate aggressiveness, the extent of disease, treatment response, and differentiation of benign from malignant lesions. This chapter will discuss the potential added value of FDG PET/CT in soft tissue sarcomas. © 2022 Elsevier Inc. All rights reserved.
- Trends in Melanoma Mortality in Brazil: A Registry-Based Study(2020) MARTA, Guilherme Nader; MUNHOZ, Rodrigo Ramella; TEIXEIRA, Monica La Porte; WALDVOGEL, Bernadette Cunha; CAMARGO, Veridiana Pires de; FEHER, Olavo; SANCHES, Jose AntonioPURPOSE A substantial increase in melanoma incidence has been consistently observed worldwide over the past decades. However, melanoma mortality rates have remained stable or declined over the past years in most regions. Given the paucity of melanoma mortality data for different Brazilian regions, we sought to describe melanoma mortality trends in southeastern Brazil and their relationship with demographic variables. MATERIALS AND METHODS A cross-sectional registry-based analysis was conducted to describe melanoma mortality trends in the state of SAo Paulo, Brazil, from 1996 to 2016. Demographic information from melanoma-related death records, including sex and age, was collected from the FundacAo Sistema Estadual de Analise de Dados database. The annual percentage change (APC) was calculated to identify mortality trends over the period. RESULTS An increasing melanoma mortality trend was detected among males, regardless of age (APC, 1.72%; P < .001), and was more pronounced for men >= 60 years old (APC, 2.63%; P < .001). Melanoma mortality rates have also increased for patients >= 60 years old, regardless of sex (APC, 1.11%; P < .001). A non-statistically significant increase in the overall melanoma mortality rate was observed over the 20-year period analyzed (APC, 0.36%; P = .4). CONCLUSION Our data suggest a stable melanoma mortality over the past two decades for the overall population studied; however, a significant increase in melanoma mortality rates has been demonstrated among males and in the population >= 60 years old, emphasizing the need to implement prevention strategies and expand access to effective therapies for this population. (c) 2020 by American Society of Clinical Oncology
- Tolerability of modified gemcitabine/docetaxel (split-dose) in patients with advanced soft tissue sarcomas(2016) AZEVEDO, R. G. M. V. D.; FRAILE, N.; SAADI NETO, E.; LOPEZ, R. V. M.; TOLOI, D.; HOFF, P. M.; FEHER, O.; CAMARGO, V. P. D.; MUNHOZ, R.
- Trends in melanoma mortality in Brazil: A 20-year registry-based study(2020) MARTA, G. Nader; MUNHOZ, R. Ramella; TEIXEIRA, M. La Porte; WALDVOGEL, B. Cunha; CAMARGO, V. P. D.; NARDO, M.; BARBOSA, C. Chaul de Lima; FEHER, O.; HOFF, P. M.; SANCHES, J. A.
conferenceObject Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) plus vemurafenib (V) in the phase Ill IMspire150 study.(2020) ASCIERTO, Paolo Antonio; ROBERT, Caroline; LEWIS, Karl D.; MUNHOZ, Rodrigo; LISZKAY, Gabriella; MERINO, Luis de la Cruz; OLAH, Judit; QUEIROLO, Paola; MACKIEWICZ, Jacek; LI, Haocheng; ZHU, Qian; MCNALLY, V.; MCKENNA, Edward Francis; GUTZMER, Ralf; MCARTHUR, Grant A.- Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma(2016) MOTA, Jose Mauricio; SCARANTI, Mariana; FONSECA, Leonardo G.; TOLOI, Diego Araujo; CAMARGO, Veridiana Pires de; MUNHOZ, Rodrigo Ramella; FEHER, Olavo; HOFF, Paulo M.Background: Kaposiform hemangioendothelioma (KHE) is a rare neoplasm of vascular origin that typically arises from the skin or soft tissues as a solitary tumor. The optimal therapy for this disease is still unknown. We report the case of an adult patient presenting with metastatic KHE of the spleen, who had a partial response after treatment with paclitaxel. Case Presentation: A 36-year-old man presented in November 2012 with a nontraumatic rupture of the spleen. A splenectomy was performed, and the pathology was consistent with a nonspecific vascular proliferation. Follow-up scans revealed lytic bone lesions and liver metastasis. A biopsy of the liver was performed and confirmed KHE. The decision was made to proceed with treatment with gemcitabine and docetaxel, which was discontinued due to myelotoxicity. The patient was then transferred to our institution, and a pathology review supported the diagnosis of metastatic KHE. His disease remained stable until February 2014, when he developed progression in the liver. Chemotherapy was restarted with paclitaxel, and a partial response was documented after 3 cycles. Unfortunately, disease progression occurred after 24 weeks, and subsequent treatments included prednisone, doxorubicin, interferon-a, gemcitabine, and ifosfamide, without any response. The patient developed Kasabach-Merritt phenomenon and passed away 1 week later due to a major gastrointestinal bleeding. Conclusions: This case report suggests that paclitaxel could be considered as a treatment option for advanced KHE, a rare condition for which no standard treatment exists. (C) 2016 The Author(s) Published by S. Karger AG, Basel
- Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma(2018) RIBEIRO, Mauricio Fernando Silva Almeida; SOUSA, Micelange Carvalho de; HANNA, Samir Abdallah; MALDAUN, Marcos Vinicius Calfat; KURIMORI, Ceci Obara; LIMA, Luiz Guilherme Cernaglia Aureliano de; MATTEDI, Romulo Loss; MUNHOZ, Rodrigo RamellaIntroduction. Chordomas are rare malignancies of bone origin that occur in the axial skeleton, typically the skull base and lumbar/sacral regions. Although often classified as low-grade neoplasms, its locally infiltrative behavior may result in significant morbidity and mortality. Optimal surgical resection may be curative, but up to 50% of the cases relapse within 5 years, and currently there are no systemic treatments approved in this setting. A large proportion of these tumors express stem-cell factor receptor (c-KIT) and platelet-derived growth factor receptors (PDGFRs), providing a rationale for the use of tyrosine-kinase inhibitors (TKIs). Case report. A 27-year-old male presented with recurrent chordoma of the lumbar spine 4 years after initial diagnosis. Salvage therapies in the interval included repeat resections and radiation therapy. He ultimately developed multifocal recurrence not amenable to complete excision or reirradiation. A comprehensive genomic profiling assay was performed and revealed nondrugable alterations. Decision was made to proceed with systemic treatment with pazopanib 800 mg/day, resulting in tumor reduction (-23.1% reduction in size) and prolonged disease control. Conclusion. For this patient with a multiple recurrent chordoma and limited treatment options, pazopanib resulted in sustained clinical benefit following initial tumor reduction.
conferenceObject The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis(2015) MUNHOZ, Rodrigo Ramella; PEREIRA, Allan Andresson Lima; SASSE, Andre Deeke; HOFF, Paulo Marcelo; TRAINA, Tiffany A.; HUDIS, Clifford A.; MARQUES, Ricardo JoseconferenceObject Bevacizumab (BEV)-based therapy in the treatment of recurrent glioblastoma (GBM) in patients (PTS) treated at a Brazilian cancer center(2012) MUNHOZ, Rodrigo Ramella; BRAGHIROLI, Maria Ignez Freitas Melro; REGO, Juliana Florinda De Mendonga; HOFF, Paulo Marcelo; FEHER, Olavo; KATZ, ArturBackground: Temozolomide (TMZ) both concurrently and after radiation therapy constitutes the standard of care for newly diagnosed GBM PTS. BEV is FDA approved option for recurrent high-grade gliomas PTS based on the results phase II trials. Reports of the use of BEV in these setting have been limited to USA and European academic centers thus far. Methods: We conducted a cross sectional retrospective study of 39 consecutive PTS with histologically confirmed GBM that received BEV in the second or third line setting. The main objective of this analysis was to assess the efficacy and safety of BEV given "off protocol" in an unselected cohort of PTS treated at a Brazilian teaching hospital cancer center and to compare our results to those reported by North American and European academic centers. PTS received first-line treatment with TMZ plus radiotherapy and most received maintenance TMZ and received Bev-based therapy at the time of disease progression. Main endpoints were the evaluation of progression-free survival (PFS), overall survival (OS) and safety. Results: Between 2007 and 2011, 39 PTS with recurrent GBM that received BEV in second (92%) or third-line (8%) were identified. Seven PTS progressed during concomitant RT and TMZ, and 40 during or after TMZ maintenance. 72% were male; median age: 56 years (range 22-79). Most patients (89,7%) received BEV in combination with irinotecan, and the median number of cycles, regardless of combination, was 14. Reasons for BEV discontinuation were disease progression in 79,5% and toxicity in 4 patients. There was one treatment related death due to thrombocytopenia and bleeding. Twenty-four PTS (61,5%) achieved an objective response with BEV. Median PFS of the patients that received BEV in either second or third line was 7.5 months and median OS was 22.6 months. No bowel perforations or any unexpected toxicities occurred. Conclusions: This constitutes the first report of recurrent GBM PTS treated with Bev in the Southern Hemisphere. In this unselected "real life" cohort of PTS with recurrent GBM we have been able to reproduce and confirm the efficacy and safety of this agent used in the treatment of GBM in the second and third line setting.conferenceObject Efficacy of second line treatment with etoposide and ifosfamide in adult patients with advanced Ewing Sarcoma family tumors(2017) NARDO, M.; ZAMBRANO, E. M.; VICENTINI, M. F.; TOLOI, D.; CAMARGO, V. P.; FEHER, O.; MUNHOZ, R.